Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 3/20 | 0.42 |
| ▸ | MMP9 | P14780 | 3/20 | 0.42 |
| ▸ | MMP13 | P45452 | 3/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6415132 | 0.99 | CCR5 (0.52) | CCR5ALDH1A1SIGMAR1UTS2RMMP1 | |
| SCHEMBL6413008 | 0.96 | CCR5 (0.56) | CCR5ALDH1A1SIGMAR1UTS2RMMP1 | |
| SCHEMBL6410264 | 0.95 | CCR5 (0.55) | CCR5ALDH1A1SIGMAR1UTS2RMMP1 | |
| Hydrochloric Acid SCHEMBL6409470 | 0.95 | CCR5 (0.55) | CCR5ALDH1A1SIGMAR1UTS2RMMP1 | |
| Hydrochloric Acid SCHEMBL6409167 | 0.94 | CCR5 (0.55) | CCR5ALDH1A1SIGMAR1UTS2RMMP1 | |
| SCHEMBL6409316 | 0.93 | SIGMAR1 (0.44) | CCR5ALDH1A1SIGMAR1UTS2RCNR2 | |
| SCHEMBL6417585 | 0.93 | SIGMAR1 (0.45) | CCR5SIGMAR1MMP1MMP9MMP13 | |
| Hydrochloric Acid SCHEMBL6413451 | 0.93 | SIGMAR1 (0.43) | CCR5ALDH1A1SIGMAR1UTS2RCNR2 | |
| Hydrochloric Acid SCHEMBL6409005 | 0.92 | SIGMAR1 (0.45) | CCR5SIGMAR1MMP1MMP9MMP13 | |
| SCHEMBL6416612 | 0.91 | ROCK2 (0.47) | CCR5UTS2RMMP1MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | CCR5 4/4885ALDH1A1 869/4885SIGMAR1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.